Illumina, Inc. is evaluating divestiture options for its Grail Inc. liquid-biopsy subsidiary after the European Commission (EC) ordered Illumina to divest Grail to ensure competition in the in vitro diagnostics market.
Regulators on both sides of the Atlantic have been telling Illumina that its acquisition of Grail in 2020 violated their anti-trust regulations, but the company has persisted, hoping to successfully overturn both rulings on appeal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?